Related Experiment Video
Updated: May 30, 2026

In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an
Ulrika Furustrand Tafin1, Ivana Majic, Cyrine Zalila Belkhodja
1Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.
Abstract:
For enterococcal implant-associated infections, the optimal treatment regimen has not been defined. We investigated the activity of daptomycin, vancomycin, and gentamicin (and their combinations) against Enterococcus faecalis in vitro and in a foreign-body infection model. Antimicrobial activity was investigated by time-kill and growth-related heat production studies (microcalorimetry) as well as with a guinea pig model using subcutaneously implanted cages. Infection was established by percutaneous injection of E. faecalis in the cage. Antibiotic treatment for 4 days was started 3 h after infection. Cages were removed 5 days after end of treatment to determine the cure rate. The MIC, the minimal bactericidal concentration (MBC) in the logarithmic phase, and the MBC in the stationary phase were 1.25, 5, and >20 μg/ml for daptomycin, 1, >64, and >64 μg/ml for vancomycin, and 16, 32, and 4 μg/ml for gentamicin, respectively. In vitro, gentamicin at subinhibitory concentrations improved the activity against E. faecalis when combined with daptomycin or vancomycin in the logarithmic and stationary phases. In the animal model, daptomycin cured 25%, vancomycin 17%, and gentamicin 50% of infected cages. In combination with gentamicin, the cure rate for daptomycin increased to 55% and that of vancomycin increased to 33%. In conclusion, daptomycin was more active than vancomycin against adherent E. faecalis, and its activity was further improved by the addition of gentamicin. Despite a short duration of infection (3 h), the cure rates did not exceed 55%, highlighting the difficulty of eradicating E. faecalis from implants already in the early stage of implant-associated infection.
Insights
Daptomycin showed better activity than vancomycin against enterococcal implant infections. Combining daptomycin or vancomycin with gentamicin improved cure rates in an animal model, though eradication remains challenging.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Enterococcal implant-associated infections lack defined optimal treatment regimens.
- Enterococcus faecalis is a common pathogen in these difficult-to-treat infections.
- Evaluating antibiotic efficacy against adherent bacteria is crucial for treatment strategies.
Purpose of the Study:
- To investigate the in vitro and in vivo activity of daptomycin, vancomycin, and gentamicin against Enterococcus faecalis.
- To assess the efficacy of antibiotic combinations in a foreign-body infection model.
- To determine optimal treatment strategies for enterococcal implant-associated infections.
Main Methods:
- In vitro studies included time-kill assays and microcalorimetry.
- A guinea pig foreign-body infection model with subcutaneously implanted cages was utilized.
- Antibiotic treatment (daptomycin, vancomycin, gentamicin, and combinations) was administered for 4 days, starting 3 hours post-infection.
Main Results:
- Daptomycin demonstrated greater activity than vancomycin against adherent E. faecalis in vitro.
- Gentamicin, even at subinhibitory concentrations, enhanced the activity of daptomycin and vancomycin in vitro.
- In the animal model, daptomycin achieved a 55% cure rate when combined with gentamicin, compared to 25% for daptomycin alone. Vancomycin with gentamicin achieved 33% versus 17% alone.
Conclusions:
- Daptomycin is more effective than vancomycin against adherent E. faecalis, with synergistic improvement observed when combined with gentamicin.
- The combination of daptomycin and gentamicin offers the highest cure rate (55%) in this early-stage implant infection model.
- Eradicating E. faecalis from implants, even in the early stages, remains a significant clinical challenge, necessitating further research into treatment optimization.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Estimation of k and VD of Aminoglycosides
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

